The Significance of Matrix Metalloproteinases in the Immunopathogenesis and Treatment of Multiple Sclerosis by Mirshafiey, Abbas et al.
Sultan Qaboos University Med J, February 2014, Vol. 14, Iss. 1, pp. e13-25, Epub. 27TH Jan 14
Submitted 26TH May 13
Revisions Req. 18TH Jun & 1ST Aug 13; Revisions Recd. 28TH Jun & 2ND Sep 13
Accepted 19TH Sep 13
Multiple sclerosis (MS) is the most common prototypic inflammatory disorder, characterised by inflammation, 
oligodendrocyte depletion, reactive astrogliosis 
and demyelination in the brain, optic nerve and 
spinal cord.1 MS plaque is the major pathological 
hallmark of MS. It is a unique feature of central 
nervous system (CNS) demyelination, which is 
characterised by oligodendrocyte destruction along 
with the loss of myelin, axonal damage and loss, and 
glial scar formation.2
MS usually occurs in young adults and is more 
common in women than men, with about 300,000 
patients suffering from MS in North America alone. 
Literature reviews robustly imply an increased 
prevalence of MS in recent times.3
MS patients show a variety of clinical symptoms, 
including visual difficulties, muscle weakness, 
sensory damage and difficulties with speech and 
coordination. Briefly, there are four types of MS, 
with each having a mild, moderate or severe course.4 
Most patients (~85%) initially experience relapsing-
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abstract: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). The major 
pathological outcomes of the disease are the loss of blood-brain barrier (BBB) integrity and the development 
of reactive astrogliosis and MS plaque. For the disease to occur, the non-resident cells must enter into the 
immune-privileged CNS through a breach in the relatively impermeable BBB. It has been demonstrated that 
matrix metalloproteinases (MMPs) play an important role in the immunopathogenesis of MS, in part through 
the disruption of the BBB and the recruitment of inflammatory cells into the CNS. Moreover, MMPs can also 
enhance the cleavage of myelin basic protein (MBP) and the demyelination process. Regarding the growing data 
on the roles of MMPs and their tissue inhibitors (TIMPs) in the pathogenesis of MS, this review discusses the role 
of different types of MMPs, including MMP-2, -3, -7, -9, -12 and -25, in the immunopathogenesis and treatment 
of MS.
Keywords: Multiple Sclerosis; Blood-Brain Barrier; Matrix Metalloproteinases; Inflammation; Central Nervous 
System.
امللخ�ص: يعد مر�س �لت�صلب �لع�صبي �ملتعدد )MS( �أحد �أمر��س �ملناعة �لذ�تية يف �جلهاز �لع�صبي �ملركزي )CNS(. ونتيجه لالإ�صابه به يحدث 
خلل يف �صالمة حاجز �لدم يف �لدماغ )BBB( �إىل جانب تطور يف رد فعل �لدباق �لنجمي و لويحات �لت�صلب �لع�صبي �ملتعدد. يحدث هذ� �ملر�س عندما 
تدخل �خلاليا غري �ملقيمه �ىل �جلهاز �لع�صبي �ملركزي �ملحمي مناعيا من خالل ثغرة يف حاجز �لدم يف �لدماغ. وقد تبّي �أن �الأنزميات �ملعدنية �ملحللة 
للربوتي )MPPs( تلعب دور� مهما يف تطور مر�س �لت�صلب �لع�صبي �ملتعدد, من خالل تعطيل حاجز �لدم وتوجيه �خلاليا �اللتهابية �ىل �جلهاز �لع�صبي 
باملعلومات  يتعلق  فيما  �أما  ونزع غطائه.  للمايلي  �ال�صا�س  بروتي  �النق�صام يف  بتعزيز  تقوم  �أن  �الأنزميات ميكن  �أن هذه  ذلك  �ىل  ي�صاف   . �ملركزي 
هنا  فاننانناق�س  �ملتعدد,  �لع�صبي  �لت�صلب  مر�س  يف  �لت�صبب  يف  �الن�صجة  يف  مثبطاتها  و  للربوتي  �ملحللة  �ملعدنية  �الأنزميات  دور  حول  �ملتنامية 
دور�الأنو�ع �ملختلفة من �الأنزميات �ملعدنية �ملحللة للربوتي , مبا يف ذلك MMP-2، -3، -7، -9، -25, يف تطور مر�س �لت�صلب �لع�صبي �ملتعدد 
وعالجه.
مفتاح الكلمات: مر�س �لت�صلب �لع�صبي �ملتعدد؛ حاجز �لدم يف �لدماغ؛ �الأنزميات �ملعدنية �ملحللة للربوتي؛ �لتهاب؛ �جلهاز �لع�صبي �ملركزي.
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remitting MS (RRMS); the majority is predisposed 
to the establishment of secondary-progressive MS 
(SPMS) which is characterised by an initial RRMS 
disease course followed by a progression with or 
without occasional relapses, minor remissions, and 
plateaus. Nearly 10% of patients display primary-
progressive MS (PPMS), which indicates the disease 
progression from onset with occasional plateaus 
and temporary minor improvements. Finally, the 
least common form of the disease is progressive-
relapsing MS (PRMS), which occurs in ~5% of MS 
patients and is characterised by the progressive 
disease from onset, with clear acute relapses, with 
or without full recovery.5,6
Although the precise cause of MS is unknown, 
the aetiology of MS seems to be linked to a variety of 
genetic and environmental factors. Current opinion 
suggests that the activation of autoreactive, adaptive 
and innate immune responses which target neural 
antigens leads to MS.2 The self-reactive T cells are 
the main factors in the immunopathogenesis of MS. 
There is consistent evidence showing the central role 
of T helper 17 cell (Th17)-producing interleukin 17 
and interferon γ (IFN-γ)-secreting type 1 T helper 
(Th1) cells in the disease’s development, in part 
through the secretion of inflammatory mediators 
and the activation of microglial cells.7
Although the microglia is involved in the 
phagocytosis of myelin debris and apoptotic cells 
during demyelination, the activation of the microglia 
and the release of inflammatory mediators has been 
suggested as a possible mechanism by which innate 
immunity enhances the demyelination process in 
MS.2,8 Therefore, microglial cells, which constitute 
about 10% of the CNS, are one of the first cells that 
cause neuronal damage and play an important role 
in neuroinflammatory processes.8
In MS, neural factors generated by acute stress, 
including myelin basic protein (MBP), substance P 
and corticotropin-releasing hormones, can activate 
brain mast cells to release inflammatory mediators 
and stimulate the autoreactive T cells.9
Astrocytes are involved in nearly all 
immunopathological processes in the brain. It 
has been reported that astrocytes could release 
factors which regulate the oligodendrocyte 
progenitor differentiation and myelin formation.1,10 
Oligodendrocytes enhance the inflammatory 
cytokine production in T cells as well as chemokines 
that may recruit additional peripheral inflammatory 
leukocytes.10 The localisation of astrocytes in MS is 
similar to mast cells in the perivascular area.11
Two types of phagocytes (including the 
microglia and inflammatory macrophages) 
in MS and its animal model, experimental 
autoimmune encephalomyelitis (EAE), are 
derived from proliferating resident precursors 
and the recruitment of blood-borne progenitors, 
respectively.12 These phagocytes and astrocytes 
can recognise pathogen-associated molecular 
patterns (PAMPs) via Toll-like receptors (TLRs) 
and generate pro-inflammatory signals that 
trigger adaptive immune responses. Moreover, 
these cells enhance the autoimmune responses 
through the secretion of effector molecules such 
as nitric oxide (NO), matrix metalloproteinases 
(MMPs) and calpain-1 that may also play a role in 
the initiation of myelin and axon damage.13,14 The 
recruited inflammatory cells are mainly composed 
of cluster of differentiation 4 (CD4+) T cells, B 
cells, monocyte/macrophages, neutrophils and 
dendritic cells.15 However, these non-resident cells 
have to penetrate the blood-brain barrier (BBB) to 
reach the immunologically-privileged CNS.16 The 
BBB is a dynamic interface that separates the brain 
from the circulatory system and protects the CNS 
from potentially harmful chemicals. Therefore, the 
BBB restricts the exchange of humoral factors and 
cells between the blood and brain, thus playing a 
crucial role in maintaining cerebral homeostasis. 
Disruption of the BBB is considered an initial key 
step of the disease process in MS.17
The breakdown of the BBB usually lasts for 
about a month and then resolves, leaving a site of 
damage that can be investigated by conventional 
magnetic resonance imaging (MRI).18 In MS, the 
BBB may be impaired by MMPs attacking the basal 
lamina macromolecules before the formation of 
demyelinating foci or T-cell infiltration around 
the small vessels; however, once the BBB is 
disrupted, the massive infiltration of T cells, the 
augmented expression of adhesion molecules on 
the endothelial cell surface and the leakage of the 
inflammatory cytokines and antibodies aggravate 
the MS lesions.17 In the brains of MS patients, 
mast cells are placed on the perivascular area and 
secrete numerous vasoactive molecules and pro-
inflammatory mediators that can contribute to the 
BBB disruption.9 
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different physiological and pathological processes, 
such as placental development, morphogenesis, 
reproduction, wound repair, inflammation, 
angiogenesis, neurological disorders, and cancer 
cell invasion and metastasis.24
MMPs affect a variety of extracellular proteins 
in the CNS, including cytokines, chemokines, 
antimicrobial peptides and immune regulatory 
proteins. Using quantitative reverse transcriptase 
polymerase chain reaction (RT-PCR), Bar-Or et 
al. systematically evaluated the expression of 23 
MMP members in subsets of leukocytes isolated 
from the blood of normal populations. They found 
a specific pattern of MMP expression in different 
cellular populations: MMP-11, -26 and -27 were 
The MMPs or matrixins represent a large family 
of zinc-dependent proteolytic enzymes that are 
known for their capacity to degrade extracellular 
matrix (ECM) components.19 MMPs are a family of 
proteases, classified into subfamilies based on their 
substrate preferences. Currently, there are 23 known 
MMPs, including: gelatinases (MMP-2 and ‒9); 
collagenases (MMP-1, -8, -13 and -18); stromelysins 
(MMP-3, -10 and -11); matrilysins (MMP-7 and 
-26); membrane type (MT) MMPs (including 
MMP-14, -15, -16, -17, -24 and -25), and a group 
of unnamed members (MMP-11, -12, -19, -20, -21, 
-23a, -23b, -27 and -28). All MMPs are secreted as 
proenzymes and require extracellular activation.20–23 
Recent findings indicate that MMPs are involved in 
Figure 1: In multiple sclerosis, matrix metalloproteinases (MMPs) are expressed in the central nervous system (CNS) by 
various cell types, including vascular endothelial cells, neuron, reactive astrocytes and the microglia, and accumulated 
inflammatory cells. In the CNS, the high numbers of MMPs lead to the perpetuation of neuroinflammation, which 
contributes to myelin degradation and axonal damage. 
BBB = blood-brain barrier; MBP = myelin basic protein; MAG = myelin-associated glycoprotein.
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plentiful in B cells, while MMP-15, -16, -24 and -28 
showed up more often in T cells. The majority of 
MMP members are reported in monocytes: MMP-
1, -3, -9, -10, -14, -19 and -25. In addition, MMP-
2 and -17 were mainly represented in monocytes, 
although B lymphocytes had significant amounts of 
these MMPs.25,26
Growing evidence implies that the normal, 
mature CNS contains low or non-detectable levels 
of most MMPs; the principal cells that express 
these MMPs are perivascular and parenchymal 
microglia. On the other hand, studies on the 
serum, cerebrospinal fluid (CSF) and brain 
tissue of MS patients have shown an increase of 
MMP-1, -2, -3, -7, -9, -12 and -14 activity.27–29 Some 
data suggest that microglial-derived MMPs may 
mediate the turnover of the CNS’s ECM under 
normal conditions in microglial nodules, but in 
many neuroinflammatory conditions, such as 
encephalitis, meningitis, brain tumours, cerebral 
ischaemia, Guillain-Barré syndrome and MS, these 
enzymes are significantly upregulated.30–32
In neuroinflammatory conditions, MMPs are 
expressed in the CNS by a variety of cell types, 
including vascular endothelial cells, meninges, 
resident cells such as neuronal cells, astrocytes, 
microglial cells and accumulated inflammatory 
cells [Figure 1]. It has been shown that astrocytes 
can release MMP-1, -2, -3 and -9, whereas the 
microglia secretes MMP-7, -9, -12 and -19.33,34 Most 
Table 1: Some important matrix metalloproteinases in the central nervous system and their relationship with the 
pathogenesis of multiple sclerosis
MMP MW in kDa Cell source Functions TIMPs
Pro-enzyme Active form





•Activator for MMP‒2 and ‒9 
•Breaks down the interstitial collagens 
(types I, II and III)
TIMP‒1





•BBB disruption, which facilitates 
immune cell transmigration into the 
CNS 
•Fragmentation of the MBP 
•Demyelination 
•Axonal injury 
•Activator for MMP‒1 and ‒9
TIMP‒2 and 
TIMP‒4
MMP‒3 57 54 Astrocytes, 
monocytes, 
macrophages, 
endothelial cells and 
microglia
•BBB disruption 
•Activates microglia or ‘white matter’ 
brain cells 
•Activator for MMP‒1, ‒7 and ‒9 
•Normal functioning as neuronal 
migration 
•Neurite outgrowth and CNS 
development 
•Stem cell migration 
•Neuroprotection  
•Remyelination in the injured CNS
TIMP‒1 and 
TIMP‒3
MMP‒7 29 20 Microglia, 
monocytes and 
macrophages
•Cleaves NR1 (an obligate sub-unit of 
the NMDA receptor) 
•Activator for MMP‒1, ‒2 and ‒9
TIMP‒1






and CCR2+ CCR5+ 
T cells
•Increases the permeability of the BBB 
•Facilitates the infiltration of 
leukocytes into the CNS 
•Myelin sheath degradation  
•Neuronal damage
TIMP-1




•Potentially partakes in myelinogenesis 
TIMP‒1
MMP‒14 66 ~54 Monocytes •Activator for MMP‒2 




MMP = matrix metalloproteinase; MW = molecular weight; kDa = kilodaltons; TIMP = tissue inhibitors of metalloproteinases; BBB = blood-brain 
barrier; CNS = central nervous system; MBP = myelin basic protein; NMDA = N-methyl-d-aspartate.
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Findings on MMP secretion by blood monocytes 
can be useful in improving our understanding of the 
immunopathogenesis of MS.41 
To summarise, it seems that monocytes are key 
contributors to the neuroinflammatory process in 
MS through a mechanism that involves the high 
expression of different MMPs, such as MMP-1, -2, 




Matrix metallopeptidase-2 (also known as gelatinase 
A and a 72 kilodalton [kDa] type II collagenase) plays 
an important role in inflammation and immunity in 
addition to its physiological function in degrading 
and remodelling the ECM. The expression of 
MMP-2 is upregulated in many human diseases 
as well as in animal models of inflammatory and 
immune diseases. Bar-Or et al., following analyses 
of all MMPs in leukocytes, implicated monocytes 
as major inflammatory cells in MS. They found 
higher levels of monocyte-expressed MMP-2 and 
-14 in MS patients compared to normal subjects.25 
Moreover, another report suggested that MMP-2 
can be expressed not only in monocytes but also in 
the astrocytes, microglia and macrophages.43
Although the correlation between the frequency 
of macrophages and reactive glial cells with axon 
injuries in the acute plaques is well-established, little 
is known about the precise role of MMP-2 in the 
immunopathogenesis of MS.44,45 Anthony et al.46 and 
Maeda et al.32 showed that MMP-2 was upregulated 
not only in plaques but also in the seemingly normal 
white matter adjacent to the acute plaques. In 
these acute plaques, the myelin was degraded and 
engulfed by the reactive glial cells and macrophages, 
leading to demyelination.35 In addition, Newman et 
al. showed that a microinjection of MMP-2 into rat 
subcortical white matter led to axonal injury.47
It seems that MMP-2 plays a key role in the 
BBB disruption, which facilitates immune cell 
transmigration into the CNS and the development 
of MS.38,43,48 Therefore, the downregulation of MMP-
2 may inhibit the BBB disruption and migration of 
the inflammatory cells to the CNS. Although little 
is known about the involvement of MMP-2 and its 
tissue inhibitor TIMP-2 in MS, it has been shown 
that TIMP-2 is elevated in the monocytes of MS 
microvessel endothelial cells in the CNS express 
MMP-3 and -9 but not -1 or -2. Also, the majority of 
macrophages in active MS and necrotic lesions are 
positive for MMP-l, -2, -3, -7, -9 and -19, whereas 
chronic MS lesions have fewer MMP-positive 
macrophages.32,35 Neurons may also release MMPs. 
It is reported that in normal adult rat brains, MMP-
9 (but not -2) is highly expressed by neurons and 
localised in neuronal cell bodies and dendrites.36
In the damaged sites of the CNS, there are 
complex and dynamic regulations of MMP 
expression by different cell types.32 The imbalance 
between MMP activity and the inhibitory action 
of tissue inhibitors of metalloproteinases (TIMPs) 
are implicated in MS development [Table 1], as 
one of the MMP roles may be to facilitate the 
transmigration of circulating leukocytes into the 
CNS.25 Therefore, it is possible that the MMPs 
attack the basal lamina macromolecules that line 
the blood vessels, disrupting the BBB’s integrity.31
Moreover, MMPs can be involved in the 
fragmentation of MBP and myelin-associated 
glycoprotein (MAG), and injury to the myelin. 
In the CNS, the MBP gene is expressed in the 
oligodendrocytes and is named classic-MBP; in the 
immune cells it is named golli-MBP.37 Therefore, 
MMP-mediated proteolysis of the MBP isoforms is 
a source of immunogenic peptides in autoimmune 
MS.38 Consequently, through the remodelling of 
the blood vessels, MMPs cause hyalinosis and 
gliosis, and they attack the myelin, disrupting the 
myelin sheath and axons. Excessive proteolytic 
activity is detected in the CSF and blood of patients 
with acute MS. Moreover, MMPs are induced in 
immunological and non-immunological forms of 
demyelination.31
Regarding the high expression of many MMPs 
by monocytes which facilitate the transmigration of 
the leukocytes, Bar-Or et al. showed that monocytes 
migrate more rapidly through the BBB than T or B 
lymphocytes, in vitro.25 Although data about the 
role of MMPs in monocyte trafficking are limited, 
Lucchinetti et al.18 suggested that the frequency of 
macrophages/microglia in MS is approximately 10 
times higher compared to lymphocytes. Also, in 
active MS lesions, macrophages were found to be 
positive for MMP-2, -7, -9, -12 and -19.39,40 Since 
monocytes constitute a major cell population in 
acute MS lesions, it may be possible that MMP 
secretion facilitates their entrance into the CNS. 
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patients. However, it should be noted that there are 
no data regarding the functionality of TIMP-2 in 
MS patients. 
TIMP-2 is an inhibitor of activated MMPs; it 
inhibits the cell surface activation of pro-MMP-2 
by MMP-14.25,49 MMP-14 acts as a receptor for 
TIMP-2 (but not TIMP-1) and the pro-MMP-2/
TIMP-2 complex, thereby facilitating the activation 
of pro-MMP-2. In addition, the serum MMP-
2:TIMP-2 ratio may represent a useful indicator 
for monitoring the MS patient during a recovery 
phase.45 Benesová et al. observed in 2009 that 
there was a significant elevation in MMP-2 serum 
levels and the MMP-2:TIMP-2 ratio in the PPMS 
and SPMS groups compared to the RRMS group. 
This increase was also associated with the level 
of disability in the patient and the severity of the 
disease.43 Thus, it seems that MMP-2, -14 and 
TIMP-2 can be considered interesting targets for 
potential therapeutic interventions to inhibit the 
entry of monocytes into the CNS, and to alleviate 
injuries of the CNS in MS patients.25 
Matrix 
Metalloproteinase-3
Also known as stromelysin‒1, MMP-3 is an 
enzyme involved in ECM remodelling. MMP-3 is 
an activator of other MMPs, including MMP-1, 
-7 and -9.50 It has been demonstrated that MMP-
3 contributes to different pathological conditions, 
such as rheumatoid arthritis (RA), asthma, 
cancer and neurological disorders, including MS, 
Parkinson’s disease (PD) and Alzheimer’s disease 
(AD).51 In MS, the increased circulatory level of 
MMP-3 correlates with disease activity in RRMS. 
This may contribute to the breakdown of the BBB 
at the time of relapse.52 Moreover, the release of 
MMP-3 into the ECM activates microglial or brain 
cells in the white matter.53 Some evidence strongly 
suggests that the distinctive signal of neuronal 
apoptosis is the release of the active form of MMP-
3 that activates the microglia and subsequently 
exacerbates neuronal degeneration.54 It has been 
shown consistently that the inhibition of MMP-3 
leads to the suppression of inducible nitric oxide 
synthase, (iNOS), proinflammatory cytokines and 
the inflammatory transcription factors nuclear 
factor kappa B (NF-κB), activator protein 1 (AP1) 
and mitogen-activated protein kinases (MAPKs) in 
the microglia.53
Interestingly, it has been reported that MMP-
3 can be involved in normal CNS-remodelling 
and in the remyelination process, as shown by the 
strict spatiotemporal MMP-3 upregulation in the 
injured CNS, which may contribute to stem cell 
migration, neuroprotection and remyelination in 
the injured sites.51 An involvement of MMP-3 in 
remyelination during the regenerative period after 
a CNS injury was demonstrated for the first time 
in the murine cuprizone-induced demyelination 
model. It was reported that not only during the 
early demyelination stage, but also during the stage 
of remyelination, MMP-3 was highly expressed 
in astrocytes of the corpus callosum. Although 
the exact mechanism is unknown, MMP-3 might 
be involved in remyelination through enhancing 
insulin growth factor (IGF) secretion, which is 
essential for the proliferation and differentiation 
of myelin-forming cells.55–57 In addition, MMP-3 
might stimulate remyelination by removing and 
cleaving the myelin debris, which inhibits the 
oligodendrocyte precursor cell differentiation.51,58
Matrix 
Metalloproteinase-7 
Also known as matrilysin, MMP-7 is increased in 
the serum, CSF and brain tissues of MS patients.27 
It has been shown that the messenger ribonucleic 
acid (mRNA) levels of MMP-7 and -9 are elevated 
in all stages of lesion formation in MS patients.59 
Moreover, MMP-7 expression was found to be 
upregulated in microglia/macrophages within acute 
MS lesions. In chronic MS lesions, the expression 
of MMP-7 was confined to the macrophages 
within the perivascular cuffs, whereas only a 
low level of MMP-7 expression was detected in 
normal brain tissue.46 In a study by Cossins et al., 
MMP-7 immunoreactivity was weakly detected in 
microglial-like cells in normal brain tissue sections, 
and was very strongly detected in the parenchymal 
macrophages in active demyelinating MS lesions. 
MMP-7 immunoreactivity was not detected in 
macrophages in the spleen or tonsils, indicating that 
it is specifically induced in infiltrating macrophages 
in active demyelinating MS lesions.35 Elevated levels 
of MMP-7 and -9 have also been detected in cases 
of EAE. In one study of adoptive transfer EAE, 
mRNA for MMP-7 was increased, with maximum 
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granulocyte chemotactic protein-2 was decreased.66 
It was found that young MMP-9 knockout mice are 
partially resistant to the development of EAE.61,67 
However, when both gelatinases (MMP-2 and -9)
were genetically knocked out, a complete resistance 
against myelin oligodendrocyte glycoprotein 
peptide-induced EAE was observed.68 The latter 
study is important as it shows that many proteinases 
act in these  cascades or networks.69
Indeed, investigations of MMP-2 indicate that it 
is able to activate MMP-9 in vitro.70 Both enzymes 
thus reinforce each other and they also share a 
number of substrates, including denatured collagen 
or gelatin.71 In addition, decreased serum MMP-
8 and -9 levels were correlated with a decreased 
number of contrast-enhanced T2-weighted MRI 
lesions in MS patients.72 In the same study, MS 
patients treated with interferon β 1b (IFN-β1b) 
showed a reduction in serum MMP-8 and -9 in 
parallel with the disease stabilisation. The authors 
concluded that the serial measurement of MMPs 
and other inflammatory mediators may serve 
as sensitive markers for measuring therapeutic 
response to IFN-β1b during the first year of 
treatment.
As mentioned earlier, it is suggested that MMP-
9 has a role in MS by mediating T-cell migration 
through the BBB. During a relapse course, the 
CCR2+CCR5+ T cells are abundant in the CSF of 
MS patients. These T cells have the potent ability 
to produce osteopontin and MMP-9, both of which 
have an important role in the MS pathology.73 Also, 
in MS patients in the relapse phase, these subtypes 
of T cells are reactive to MBP, as this ability can 
be evaluated by IFN-γ production. Other findings 
suggested that the CCR6- subtype (but not the 
CCR6+ subtype within CCR2+CCR5+ T cells) is 
very abundant in the CSF during a MS relapse and 
can produce higher levels of MMP-9 and IFN-γ.73,74
As TIMP-1 is a tissue inhibitor of MMP-9, a 
considerable elevation in the MMP-9:TIMP-1 ratio 
and in MMP-9 serum levels was observed in MS 
patients in the RRMS and SPMS groups.43 Fainardi et 
al. have suggested that a shift in the MMP-9:TIMP-1 
ratio towards MMP-9 proteolytic activity can be 
the consequence of MS immune downregulation.75 
Moreover, using immunohistochemistry, TIMP-1 
was found to be upregulated in chronic plaques.62 
The concentrations of these metalloproteinases 
inhibitors in the CSF and plasma were low in patients 
levels at the peak of the disease.60
Matrix 
Metalloproteinase-9 
Also known as gelatinase B and type IV collagenase, 
MMP-9 is secreted from neutrophils, macrophages 
and a number of transformed cells in zymogen 
form.50 Upon activation, MMP-9 acts on many 
inflammatory processes and is involved in the 
progression of cardiovascular disease, RA, chronic 
obstructive pulmonary disease and MS.24 MMP-
9 is also important in cytokine and protease 
modulation; it degrades the serine protease 
inhibitor α1-antitrypsin, which may lead to the 
destruction of the lungs.24 Different studies have 
indicated the increased expression of MMP-9 in 
MS.61 In one study, zymography methods showed 
that MMP-9 levels were high in the CSF of MS 
patients and in patients with infections of the CNS 
and other inflammatory diseases.28 In patients with 
MS, high MMP-9 levels were associated with the 
immunoglobulin G (IgG) index. Hence, MMP-9 is 
an unspecific laboratory marker of inflammation. 
For instance, the expression of MMP-9 as well as 
other MMPs (for instance, MMP-2, -7 and -12) 
is increased in MS brain sections as measured by 
immunohistochemical analysis.32,35,46,62 In addition, 
high MMP-9 levels in serum or leucocytes were 
detected by immunochemical methods.63 Long-
term follow-up studies have enabled patterns to be 
recorded with MRI; additionally, enhanced MMP-9 
steady-state mRNA levels were measured in MS.59
In the CNS, MMP-9 can be expressed in the 
vascular endothelial cells, meninges, microglia, 
astrocytes and accumulated inflammatory cells, as 
well as in inflamed MS plaques and in the seemingly 
normal white matter or cerebral-infarction tissue.64 
It has been also observed that MMP-9 was strongly 
expressed by the neutrophils in patients up to 
one week after an infarction—at that point a large 
number of macrophages were expressing MMP-9.46 
In Wistar rat EAE models, an elevated expression 
of MMP-9 may play a role in some pathological 
changes, similar to MMP-2.65 For example, it 
increases the permeability of the BBB, facilitates 
the infiltration of leukocytes into the CNS and 
causes myelin sheath degradation and neuronal 
damage.24 Also, in MMP-9-deficient mice, the 
chemotaxis of neutrophils to intradermally-injected 
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with MS, whereas during treatment with interferon 
β (IFN-β), their concentrations increased.48,76,77 
Moreover, the levels of active MMP-9 in the serum 
and CSF of MS patients may represent indicators 
for the monitoring of disease activity. In particular, 
the serum active MMP-9:TIMP-1 ratio seems to be 
a very suitable and easily measurable biomarker of 
the continuous inflammation in MS.75 Furthermore, 
in a MS clinical trial, erythropoietin induced the 
expression of TIMP-1 in the endothelial cells, 
which helped to maintain the BBB integrity. The 
protective effects of erythropoietin were associated 
with an increase in the number of astrocytes 
expressing TIMP-1 in the brain and spinal cord in 
cases of EAE.78 It has also been demonstrated that 
there is a significant association between the gene 




MMP‒12 is a macrophage-specific MMP with a 
broad substrate specificity and is expressed in MS 
lesions at various stages.39 Moreover, the transient 
expression of MMP-12 has also been reported in 
the microglial cells and astrocytes of MS patients.39 
It has also been demonstrated that in active 
demyelinating lesions, phagocytic macrophages 
express MMP-12. Moreover, in inactive lesions and 
chronic active demyelinating lesions, lower ratios of 
phagocytic cells were MMP-12-positive.39 
Out of all of the MMPs that could be measured 
in the spinal cord tissue at the peak of the disease, 
MMP-12 is significantly upregulated.81 In contrast 
to previous data, Weaver et al. demonstrated that 
an elevation in MMP-12 expression was related to 
protection against EAE. In this study, MMP-12-null 
mice had significantly severe EAE when compared 
to the control mice. In addition, in vitro findings 
showed that the lymph node and spleen cells of the 
MMP-12-null mice had a significantly higher Th1 
to type 2 T helper cell (Th2) cytokine proportion 
compared with similar cells in the control mice. 
Evaluations of the main transcription factors of 
T cell polarisation also showed that MMP-12-null 
cells had reduced GATA-3 and increased the T-bet 
expression, a situation that is in favor of Th1 bias.82
Matrix 
Metalloproteinase-25
MMP-25 is a member of the MT MMPs, which is 
expressed almost exclusively in peripheral blood 
leukocytes and in anaplastic astrocytomas and 
glioblastomas, but not in meningiomas.83
It was previously shown that the gene expression 
of the majority of MMPs was upregulated in the 
spinal cords of Swiss/Jackson laboratory (SJL) mice 
with severe EAE. Here, four of the six MT MMPs 
(MMP-15, -16, -17 and -24) were downregulated 
and the two remaining MT MMPs (MMP-14 and 
-25) were upregulated in whole tissue.84 MMP-25 
proteolysis can inactivate a MS regulator known 
as αB-crystallin. Therefore, MMP-25 functions and 
their restricted cell/tissue expression patterns play 
an important role in demyelinating diseases such as 
MS.37,85 MMP-25 cleaves golli-MBP isoforms in the 
immune cells, therefore stimulating specific clones 
of the autoreactive T cells.37 It is possible that the 
transmission of these autoreactive T cells, through 
the disrupted BBB, and the appearance of MBP in 
the neuronal cells can lead to inflammation and 
self-reactive responses. The activation of different 
elevated MMPs and the dysregulation of TIMPs 
enhances inflammation, autoreactive responses, 
MBP cleavage and demyelination and, consequently, 
the development of MS.37,85 
Matrix Metalloproteinase-
based Therapeutic 
Approaches to Multiple 
Sclerosis
In view of the above, it seems that the direct 
inhibition of proteolysis or the induction of a 
balance between the endogenous proteinases 
and their natural inhibitors could be possible 
approaches to MS treatment. However, further 
proof is needed to demonstrate the pathogenic 
role of extracellular proteolysis.86 Generally, the 
role of MMP involvement in pathology is that of 
matrix degradation, so MMP inhibition may be of 
therapeutic benefit. 
The first disease targeted with MMPs was RA but 
the range of potential applications has broadened 
to include the treatment of cancer.87 However, the 
multiple roles of MMPs in the CNS make them a 
therapeutic target for the treatment of neurological 
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to a greater alleviation of the EAE severity score 
and histological outcomes, compared to either 
medication alone.106 However, because several 
MMPs are elaborated, it seems that a non-selective 
MMP inhibitor might be more efficient than those 
that target only specific MMPs or subclasses of 
the MMP family. It is suggested that current MMP 
inhibitors should only be used in short treatment 
courses, so that they do not inhibit the MMP-
mediated repair processes that subsequently 
ensue after an injury. Thus, careful selection of 
the time frames and doses of MMP inhibitors is 
recommended and patients can benefit from their 
utilisation in neurological conditions.88
Another strategy to treat MS is targeting the 
upstream molecules which regulate the expression 
of MMPs and TIMPs. For instance, the ECM 
metalloproteinase inducer EMMPRIN (also known 
as CD147) induces MMPs and this constitutes 
a new therapeutic target.107 It is reported that 
EMMPRIN is upregulated on the peripheral 
leukocytes before the onset of EAE. In brain 
sections of EAE cases, EMMPRIN expression was 
localised with MMP-9 protein and activity. The 
increased EMMPRIN levels were also characteristic 
of brain samples from MS subjects, particularly in 
plaque-containing areas. As EMMPRIN regulates 
leukocyte trafficking by increasing MMP activity, it 
may be a novel therapeutic target in the treatment 
of MS.107 Additionally, in keeping with this concept 
to interfere with the proteinase/inhibitor balances 
in MS, statins have also been studied as they have 
been shown to reduce the expression level of MMP-
9.108,109
The effect of intravenous IgG in MS is disputed; 
however, it has been reported in animal models that 
intravenous IgG might be effective as a prophylaxis, 
preventing disease development, and exerting its 
function by suppressing the activation of MMPs-2 
and -9 by blocking MMP activities at the interface 
between the blood stream and CNS.110
Another interesting strategy is the control of 
MMP regulator cytokines and chemokines; by 
using neutralising antibodies or pharmacological 
antagonists against cytokines, chemokines and/or 
their receptors may bring considerable change in 
the therapeutic landscape for MS.86,111
disorders. Further complications are that the 
various MMP members induce or compensate for 
one another, and most MMP inhibitors are non-
selective for particular MMP members. There is 
also the likelihood that, while MMP inhibitors may 
protect against certain of the detrimental effects of 
some MMPs, they will also block the useful actions 
of these MMPs, thus slowing disease recovery.88 The 
first synthetic MMP inhibitor was developed in the 
early 1980s as a pseudopeptide derivative based on 
the structure of the collagen molecule at the site 
of the initial cleavage by interstitial collagenase.89 
A number of synthetic inhibitors of MMP activity 
have been developed and have been shown to 
decrease the incidence and severity of EAE. These 
inhibitors include GM6001,90,91 Ro-31-9790,92 BB-
1101,93 UK221 and D-penicillamine.94 
A semi-synthetic tetracycline derivative, 
minocycline, also has a MMP inhibitory function.95 
In EAE mice models, it has been shown that 
minocycline decreases the expression and function 
of MMP-9 in T cells and attenuates the disease 
severity and neuropathology.96 In the clinical trial 
of minocycline in RRMS, it significantly decreased 
gadolinium-enhanced MRI activity within the first 
two months of treatment; this effect was associated 
with the role of MMPs in reducing disruption of 
the BBB.97 However, the decreased function of 
MMP-9 during treatment would also support this 
mechanism.98 The beneficial effect of IFN-β, which 
is the current drug in MS therapy, is also associated 
with the reduced production of MMP-9 by T cells, 
the decreased ability of T cells to transmigrate 
a basement membrane barrier and the reduced 
gadolinium-enhanced MRI activity.99–101 These 
results imply that IFN-β exerts alleviating effects 
in part through the suppression of the MMPs’ 
functions. Clinical studies support the possibility 
that IFN-β regulates MMP and TIMP-1 levels 
in patients with MS.48,102,103 However, there is no 
justified data regarding the anti-MMP effects of 
glatiramer acetate, another current drug in MS 
therapy.101 Interestingly, it has been shown that 
MMP-9 could disrupt IFN-β and that this was 
inhibited by minocycline through antagonism of 
the MMP-9 functioning.104 Thus, it seems that 
the combination of IFN-β and minocycline leads 
to promising results in MS therapy.105 It has been 
shown consistently that the combination of IFN-β 
and minocycline in the treatment of EAE leads 
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Conclusion
In MS disease, increased MMP activity and reduced 
TIMP levels contribute to a loss of the BBB integrity 
and infiltration of inflammatory immune cells to the 
CNS. Therefore, MMPs and their TIMPs play a key 
role in the immunopathogenesis of MS, and are 
suggested as potential targets to treatments. Hence, 
more research in MMPs/TIMPs domain and their 
roles in immunopathogenesis of disease might be 
recommended as a therapeutic toll for controlling 
MS.
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